REVIEW

Vascular calcifications in chronic kidney disease – clinical management

I. A. Checheriţă[1], Diana Smarandache[1], Cristiana David[1], Al. Ciocâlteu[1], Daniela Adriana Ion[2], I. Lascăr[3]

[1]Department of Nephrology, Urology and Transplant Immunology
[2]Department of Pathophysiology
[3]Department of Microsurgery and Plastic Surgery
"Carol Davila" University of Medicine and Pharmacy, Bucharest

Abstract

Chronic kidney disease (CKD) patients could present various types of calcifications causing different pathological conditions that would contribute to the renal disease progression and high risk of mortality. Extra-skeletal calcifications represent a common consequence of mineral bone disorders in CKD patients. Vascular calcifications represent a complex systemic manifestation caused by phospho-calcium homeostasis disorders, by imbalance among promoters and inhibitors of calcification and the presence of various arterial diseases and other risk factors. Consequently, vascular calcification can be considered an active pathological process that resembles osteogenesis. Therefore, before starting a suitable therapy for the prevention or delay of vascular calcifications, our recommendations are: to perform lateral abdominal radiography or CT-based techniques in CKD stages 3–5 patients for an early vascular calcification detection, to assess thoroughly patients presenting hyperphosphatemia, hyperparathyroidism, vitamin D deficiency and to understand clearly the pathophysiology of arterial calcification and calciphylaxis.

Keywords: CKD, vascular calcifications, physiopathology, risk factors, therapy management.

Introduction

In the last decades, vascular calcifications have been associated with unfavorable clinical prognostic in CKD patients, including high risk of mortality [1–7]. Vascular calcifications pathogenesis represents an imbalance between calcification promoters and inhibitors, caused by an improper mineral-bone metabolism [1, 8–12]. In addition, age, diabetes, dyslipidemia, hypertension, smoking can be considered as important risk factors not only for vascular calcification development, but also for healthy bone [1]. Furthermore, recent experimental studies reported that vascular smooth muscle cells could suffer a phenotype transformation (osteoblast-like cells) with a clear impact on vascular calcifications genesis [1, 13–18]. For this reason, similar to osteogenesis, vascular calcification can also be interpreted as an active cell-regulated pathological process [19–21].

Up to this moment, all researches have proved that calcification occurs in the intima and media of the vessel walls [1]. If the calcification of the intima usually involves the aorta and coronaries, the calcification of the media is localized in the elastic lamina of the large and medium arteries, especially in CKD and diabetes patients [1]. Additionally, it increases with age [1]. Even if, these two types of vascular calcifications determine different complications, they equally are associated with high risk of morbidity and mortality in CKD patients [1, 22–24]. In addition, there is a strong correlation among vascular calcifications and the caliber of the arteries. Rodríguez-García M *et al.* [1] study proved that vascular calcification prevalence was higher in large caliber arteries than in the medium and small once (70.7% compared to 55.6% and 14.1%, respectively). They also noticed that the severity of vascular calcifications in small caliber arteries was more important in men than in women (20.3% *vs.* 5%, *p*<0.05). Even more, hemodialysed (HD) patients presented higher prevalence of aortic calcifications compared to the general population (79% *vs.* 37.5%, *p*<0.001), with an OR of 8.7 (5–15). This difference was observed in both sexes (77.8% *vs.* 29.7% in women, *p*<0.001 and 80.3% *vs.* 45.4% in men, *p*<0.001) emphasized by women OR of 9 (3.8–21) compared to men OR of 7.7 (3.7–16.1). This experiment also noticed that renal replacement therapy (RRT) *per se* represents a severe risk factor for vascular calcifications development, especially in medium caliber arteries. Consequently, each year spent on dialysis increases the chances with 15% of having vascular calcifications, results in agreement with previous clinical trials [4, 5, 25, 26].

In concordance with data from the literature [27–30], Rodríguez-García M *et al.* [1] research reported a clear correlation between osteoporotic vertebral fractures and vascular calcifications in large and medium caliber arteries (mostly in femoral and uterine/spermatic arteries). Interestingly, this association was not proved in small arteries, maybe because of the reduced amount of muscle cells.

Although there is no consensus regarding a clear separation among intimal and medial calcification [31], there are some data from the literature suggesting these two forms of calcifications present distinct clinical features independent of one other [32]. Intimal calcification, characterized by foam cell formation, lipid accumulation, inflammation, oxidative stress and apoptosis, is tightly associated to atherosclerosis and determines focal calcification of atherosclerotic plaques [33]. On the other hand, medial calcification (arteriosclerosis or Mönckeberg's sclerosis) is a more frequent condition with increased cardiovascular risk, characterized by vessel stiffening (increased pulse pressure and elevated pulse wave velocity) [25, 33, 34]. Mostly, it affects the elderly and patients diagnosed with CKD, osteoporosis, hypertension or diabetes [33].

⊟ Vascular calcification pathogenesis

Recently, vascular calcification pathogenesis has been viewed as an active arterial biomineralization process that could also be considered as a tightly regulated form of calcified tissue metabolism [33]. Additionally, the importance of oxidative stress in vascular activation of the osteogenic gene was emphasized [33, 35–37].

A series of risk factors (hypercholesterolemia, hypertension, diabetes, and end-stage renal disease) linked to vascular calcification genesis are correlated with increased oxidative stress, which is characterized by an imbalance between oxidant production and antioxidant activity [33]. A recent study reported the importance of hydrogen peroxide (H_2O_2) in transforming the vascular smooth muscle cells phenotype in an osteogenic one, process emphasized by the presence of Runx2 elevated expression, known as an important transcription factor for osteogenic differentiation [33, 37]. The same study observed that H_2O_2 inhibition prevented vascular smooth muscle cell calcification [33, 37].

Apoptosis represents another oxidative stress pathway in signaling vascular calcification activation process by predisposing to calcium-phosphate crystals deposits formation [17, 33, 38, 39]. Additionally, reactive oxygen species (ROS) accumulation around calcified vascular cells determines osteoblast/osteoclast signaling and not macrophage one [33, 40].

Another study noticed that, *in vitro*, advanced oxidative protein products (AOPPs) contribute to vascular calcification pathogenesis by (a) increasing calcium deposition, expression of corebinding factor-alpha-1 (Cbfa-1) and osteopontin and by (b) decreasing alpha-smooth muscle actin expression in human aortic smooth muscle cells [33, 41].

As it has previously been presented, vascular calcification may be considered an actively regulated process, resembling to skeletal mineralization, because atherosclerotic plaques present bone morphogenic protein 2 (BMP2) and osteopontin [42]. Osteopontin is expressed in the outer margins and central site of coronary artery plaques [43]. In addition, hyperphosphatemia, high calcium-phosphate product levels, deficiency of calcification inhibitors, and direct effects on vascular smooth muscle cells (VSMCs) are equally involved in the calcification process [42]. In arterial calcification, medial and intimal calcium deposits present matrix vesicles influenced by cultured VSMCs that are linked to their content of calcification inhibitory factors [42], including fetuin and MGP (matrix gla protein) [44].

Converging evidence showed that most of the atherogenic factors (oxidized lipids, inflammatory cytokines, upregulated activity of monocyte–macrophages) [45], influenced by vitamin D activation [46], induce osteogenesis in human vascular cell.

It is believed that transcription factor core binding factor α_1 (Cbfa-1; encoded by the *RUNX2* gene) is responsible for the phenotypic transformation of VSMCs to osteoblast cells [42]. Cbfa1 was found in CKD patients with vascular calcification and in subjects diagnosed with atherosclerotic disease without CKD [47]. This finding emphasizes that, perhaps, intimal and medial calcification mechanisms are similar [47]. This idea can be sustained by the VSMCs pivotal role in the vascular calcification process [48].

These hypotheses are not fully supported by *in vivo* studies and cannot explain the elevated prevalence of atherosclerosis in CKD patients [42]. A research regarding coronary atherosclerotic injuries made on 27 patients diagnosed with CKD (21 on chronic dialysis) and 27 age- and sex-matched subjects from the control group reported that atherosclerotic plaques were more calcified in CKD patients [42]. Additionally, medial thickness was significantly greater in renal impairment individuals [42].

The study of Nakano T *et al.* [49] noticed, in their sample of 126 patients, that advanced atherosclerotic lesions are more frequent in patients with a lower estimated GFR linked to higher prevalence of calcified coronary lesions and thickened arterial intima. Furthermore, hypertension and diabetes were associated with high risk of calcification in subjects presenting estimated GFR <60 mL/min/1.73 m^2 [49]. If Nakano T *et al.* [49] study failed to prove any medial lesions, Fitzpatrick LA *et al.* detected concomitant intimal and medial calcifications in the coronary artery walls, lesions extended even [43].

Therefore, vascular calcification represents an active process that consists in documented morphological modifications both in intima and in medial artery that is influenced by renal impairment and consequently by the inflammatory state of patients.

⊟ Vascular calcifications – treatment options

Before presenting a suitable therapy scheme in preventing and decreasing vascular calcification development, we should emphasize that major changes in understanding uremic vascular calcification process have been made, in the last decade (Table 1) [50].

Table 1 – *A decade of progression in understanding vascular calcification in CKD patients*

Year	
2000	Coronary artery calcification is highly prevalent in young end-stage renal disease (ESRD) adults.
	Phosphate directly promotes vascular smooth muscle cell calcification (VSMC) and induces osteogenic transdifferentiation of VSMC.
2001	Vascular calcification directly and independently impairs survival in ESRD.
	Sevelamer attenuates vascular calcification in ESRD patients.
2002	Low serum fetuin-A is associated with reduced survival in ESRD.
	Survival of dialysis patients is different depending on vitamin D receptor (VDR) activators.
2003	KDOQI Guidelines.
	Complex influence of mineral metabolism upon outcome in ESRD.
2004	Calcium, phosphate, and PTH levels influence survival in ESRD.
2005	High phosphate decreases survival in CKD patients not on dialysis.
	FGF-23/Klotho interaction regulates phosphate and vitamin D metabolism
2006	Cinacalcet decreases vascular calcification *in vivo*.
	Sevelamer not superior to calcium-based binders in terms of survival.
2007	Vitamin K has anticalcification properties.
	Different VDR activators influence vascular calcification differently.
2008	Adynamic bone disease is associated with vascular calcification.
	Phosphate has negative effects on vascular health.
2009	High phosphate, high calcium, and the uremic milieu directly promote vascular calcification.
	KDIGO Guidelines.
2010	Bone and vascular health are closely related: bone–vascular axis.

The progressive loss of kidney function in chronic kidney disease (CKD) contributes to a decreased production of 1-alpha-(OH)$_2$-D3 (1,25-dihydroxy-vitamin D; calcitriol) that leads to a mineral-bone metabolism disorder associating abnormal serum calcium (Ca) and phosphorus (P) levels, and parathyroid hormone (PTH) levels, respectively [51–54]. According to some studies, only the activation of vitamin D receptors (VDRs) has some beneficial extraskeletal effects [51, 55, 56]. The development of secondary hyperparathyroidism (SHPT) may be influenced by different factors: increased PTH levels, hypocalcemia, calcitriol and vitamin D deficiency, P retention, fibroblast growth factor (FGF)-23 and various receptors (VDR, Ca-sensing receptor, FGF-23/Klotho) dysregulation [51, 52, 57, 58]. Even more, nowadays, it is worldwide accepted the positive association between mineral-bone metabolism disorders different pathological conditions, such as vascular calcifications, fractures, renal impairment progression and cardiovascular diseases. [51, 59, 60].

Because of the multifactorial involvement and severe systemic consequences, the new term CKD–mineral and bone disorder (MBD) has been proposed [51, 61] and it reflects: (a) Ca, P, PTH, or vitamin D metabolism disorders; (b) abnormalities in bone turnover, mineralization, volume, linear growth, or strength; and/or (c) vascular or other soft-tissue calcifications [51, 59–62]. This syndrome consists in six recognized types of bone disorders. First type, hyperparathyroid bone disease is characterized by high turnover, normal mineralization and any bone volume [51, 59, 63]. Mixed bone disease, the second form, consists in high turnover with mineralization defect, but with normal bone volume [51, 59, 63]. Osteomalacia presents low turnover with abnormal mineralization and low-to-medium bone volume and the adynamic bone disease is characterized by low turnover with normal mineralization and low or normal bone volume [51, 59, 63]. The last two types are amyloid bone disease and aluminum bone disease [51, 59, 63].

Summarizing, impaired VDR activation leads to cellular injury, that determines neoplasic diseases development, cell differentiation, infection, diabetes, arterial dysfunction, and vascular calcification [55, 56, 64]. Therefore, VDR activators should be included in the therapy scheme in CKD patients with vascular calcifications [61].

Recently, some studies suggested that excessive calcium intake might contribute to vascular and other extraskeletal calcification genesis [5, 65, 66]. For this reason, NKF–KDOQI Guidelines [60] recommends the use of non-calcium, non-magnesium, non-aluminum phosphate in RRT patients associating low parathyroid hormone, because these patients often present low-turnover bone disease, and are predisposed to extra-skeletal calcification [67].

It is essential to emphasize the idea that calcium-based phosphate binders should not be used in patients with hypercalcemia or with severe vascular calcification and a non-calcium, non-magnesium, non-aluminum phosphate binder (Sevelamer/Lantanum) could be a reliable option.

Takei T *et al.* [68] experimental study noticed that Sevelamer allows a better serum phosphorus control compared with calcium-based phosphate binder, reducing aortic calcification progression in HD individuals. Their findings showed a decrease of serum phosphorus values (from 6.7±0.7 to 6.2±0.5 mg/dL), of total cholesterol (from 158.5± 20.7 to 146.2±24.1 mg/dL) and of serum C-reactive protein (from 0.14± 0.13 to 0.08±0.11 mg/dL) in the Sevelamer group compared to calcium group. They also observed that in the Sevelamer group the mean changes of the aortic calcification index was significantly lower than in the calcium group.

In concordance with different trials, Sevelamer (available as Sevelamer carbonate – 800 mg tablet and Sevelamer hydrochloride – 400 mg or 800 mg tablet) should be used according to the following therapeutic schemes:

▪ Initial Sevelamer carbonate and hydrochloride dosage in patients not currently receiving a phosphate binder depends on serum phosphorus concentrations (Table 2) [69, 70].

Table 2 – *Initial Sevelamer carbonate and hydro-chloride dosage in patients not currently receiving a phosphate binder*

Serum phosphorus concentration [mg/dL]	Initial Sevelamer carbonate dosage	Initial Sevelamer hydrochloride dosage
>5.5 and <7.5	800 mg three times daily.	800 mg three times daily.
≥7.5 and <9	1.6 g three times daily.	1.2 g or 1.6 g three times daily.
≥9	1.6 g three times daily.	1.6 g three times daily.

▪ Initial dosage in patients being transferred to Sevelamer from calcium acetate therapy depends on current calcium acetate dosage (Table 3) [69, 70].

Table 3 – *Initial dosage in patients being transferred to Sevelamer from calcium acetate therapy*

Calcium acetate dosage	Initial Sevelamer carbonate dosage	Initial Sevelamer hydrochloride dosage
667 mg three times daily.	800 mg three times daily.	800 mg three times daily.
1.334 g three times daily.	1.6 g three times daily.	1.2 g or 1.6 g three times daily.
2.001 g three times daily.	2.4 g three times daily.	2 g or 2.4 g three times daily.

▪ Sevelamer hydrochloride dosage for all dialyzed patients depends on serum phosphorus concentrations (Table 4) [70].

Table 4 – *Sevelamer hydrochloride dosage for all dialyzed patients*

Serum phosphorus concentration [mg/dL]	Initial Sevelamer hydrochloride dosage
<3.5	Decrease dosage by one tablet (400 mg or 800 mg) per meal.
3.5–5.5	Maintain current dosage.
>5.5	Increase dosage by one tablet (400 mg or 800 mg) per meal.

Initially, Lantanum carbonate is recommended in a daily dose of 1500 mg and dosage titrate should be performed every 2–3 weeks until the serum phosphate wanted level is reached. Generally, the required total daily dose, to reduce phosphate values below 6 mg/dL, is between 1500 mg and 3000 mg.

Furthermore, according to NKF–KDOQI Guidelines [60] a 2 g/day calcium intake is sufficient in CKD patients and any supplementation may induce hyper-calcemia and consequent complications in almost 36% of individuals [71].

Although phosphate binders' administration may decrease vascular calcification progression, still their effect is not potent enough and at this moment, there are no specifically designed drugs in completely reversing vascular calcifications.

Murshed M *et al.* observed that pyrophosphate molecule (PPi), that inhibits hydroxyapatite formation and calcification process in soft tissues, is rapidly degraded by the tissue non-specific alkaline phosphatase (TNAP) and therefore it is not normally active in bone tissue [72].

Considering these data, Riser BL *et al.* study [73] proposed a new for of therapy by introducing PPi into peritoneal dialysis (PD) solution for preventing the VC progression linked to the patients' uremic condition. They provided a daily continuous administration of PPi in PD solution and observed that PPi intraperitoneum (IP) administration was completely absorbed, with minimal degradation at peritoneum level and, in addition, the maximum concentrations of PPi in plasma were lower and the time to reach these maximal values were prolonged compared to intravenous (IV) administration. Consequently, detectable levels of PPi remained in plasma following IP delivery even after eight hours post-administration, whereas after 1 hour PPi levels were not longer detected following IV administration. They concluded when PPi is delivered daily (six times per week) in a PD solution, it can prevent the development of aortic calcification and that a PD solution containing 150 μM PPi may inhibit aortic calcification. Additionally, they noticed when the PPi dose was reduced to the lower 30-μM concentration, reflecting a dose–response effect, the blockade of aortic calcification was no longer evident.

⊟ Conclusions and Future Perspectives

Chronic kidney disease patients could present various types of calcifications causing different pathological conditions that would contribute to the CKD progression and unfavorable outcome. Calcification may occur anywhere (vascular and valvular calcification, calcific uremic arteriolopathy (CUA; calciphylaxis), soft tissue and parenchymal organs, conjunctival and corneal calcification, peritoneal calcification). Frequently, metastatic, tumoral and soft tissue calcifications occur in the shoulder and hip region (*Teutschlander disease*), but there have been observed in other locations, too: hands, feet, nose, spinal canal. Unlike vascular calcifi-cations, the current international database reported just few information regarding the soft tissue calcifications incidence and clinical impact.

Extra-skeletal calcifications represent an often consequence of mineral bone disorders in CKD patients. Vascular calcifications represent a complex systemic manifestation influenced by phospho-calcium severe disorder, by the imbalance among promoters and inhibitors of calcification and the presence of other risk factors (Table 5) [74].

Table 5 – *Risk factors for vascular calcification in kidney disease*

Traditional risk factors	Non-traditional risk factors
Age	Renal impairment
Diabetes mellitus	Dialysis vintage
Hypertension	Disorders of mineral metabolism:
Dyslipidemia	▪ hyperphosphatemia; ▪ hyperparathyroidism;
Smoking	▪ changes in vitamin D metabolism; ▪ elevated FGF-23 levels.
	Inflammation and oxidative stress
	Osteogenesis factors (CBFA1/RUNX2)

Most of CKD patients present vascular calcification, but currently no effective treatment has been developed to stop the natural progression of the disease and therefore, future clinical controlled trials are needed. Before starting a suitable therapy scheme to delay vascular calcifications development, our recommendations are: (a) to perform lateral abdominal radiography or CT-based techniques in CKD stages 3–5 patients for an early vascular calcification detection, (b) to assess thoroughly patients presenting hyperphosphatemia, hyperparathyroidism, vitamin D deficiency and (c) to understand clearly the pathophysiology of arterial calcification and calciphylaxis.

References

[1] Rodríguez-García M, Gómez-Alonso C, Naves-Díaz M, Diaz-Lopez JB, Diaz-Corte C, Cannata-Andía JB; Asturias Study Group, *Vascular calcifications, vertebral fractures and mortality in haemodialysis patients*, Nephrol Dial Transplant, 2009, 24(1):239–246.

[2] Witteman JC, Kok FJ, van Saase JL, Valkenburg HA, *Aortic calcification as a predictor of cardiovascular mortality*, Lancet, 1986, 2(8516):1120–1122.

[3] Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM, *Impact of aortic stiffness on survival in end-stage renal disease*, Circulation, 1999, 99(18):2434–2439.

[4] Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM, *Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease*, Hypertension, 2001, 38(4): 938–942.

[5] Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB, *Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis*, N Engl J Med, 2000, 342(20):1478–1483.

[6] Rostand SG, *Coronary heart disease in chronic renal insufficiency: some management considerations*, J Am Soc Nephrol, 2000, 11(10):1948–1956.

[7] London GM, *Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function*, J Am Soc Nephrol, 2003, 14(9 Suppl 4):S305–S309.

[8] Goodman WG, London G, Amann K, Block GA, Giachelli C, Hruska KA, Ketteler M, Levin A, Massy Z, McCarron DA, Raggi P, Shanahan CM, Yorioka N; Vascular Calcification Work Group, *Vascular calcification in chronic kidney disease*, Am J Kidney Dis, 2004, 43(3):572–579.

[9] Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM, *Mineral metabolism, mortality, and morbidity in maintenance hemodialysis*, J Am Soc Nephrol, 2004, 15(8):2208–2218.

[10] McCullough PA, Sandberg KR, Dumler F, Yanez JE, *Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review*, J Nephrol, 2004, 17(2):205–215.

[11] Cannata-Andía JB, Rodríguez-García M, Carrillo-López N, Naves-Díaz M, Díaz-López B, *Vascular calcifications: pathogenesis, management, and impact on clinical outcomes*, J Am Soc Nephrol, 2006, 17(12 Suppl 3):S267–S273.

[12] Jono S, Shioi A, Ikari Y, Nishizawa Y, *Vascular calcification in chronic kidney disease*, J Bone Miner Metab, 2006, 24(2):176–181.

[13] Floege J, Ketteler M, *Vascular calcification in patients with end-stage renal disease*, Nephrol Dial Transplant, 2004, 19(Suppl 5):V59–V66.

[14] Giachelli CM, *Vascular calcification mechanisms*, J Am Soc Nephrol, 2004, 15(12):2959–2964.

[15] Shanahan CM, *Vascular calcification*, Curr Opin Nephrol Hypertens, 2005, 14(4):361–367.

[16] Shanahan CM, *Mechanisms of vascular calcification in renal disease*, Clin Nephrol, 2005, 63(2):146–157.

[17] Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM, *Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD*, J Am Soc Nephrol, 2004, 15(11):2857–2867.

[18] Cozzolino M, Gallieni M, Brancaccio D, *Vascular calcification in uremic conditions: new insights into pathogenesis*, Semin Nephrol, 2006, 26(1):33–37.

[19] Chen NX, Duan D, O'Neill KD, Wolisi GO, Koczman JJ, Laclair R, Moe SM, *The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells*, Kidney Int, 2006, 70(6):1046–1053.

[20] Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K, *Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins*, Kidney Int, 2002, 61(2):638–647.

[21] Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX, *Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels*, Kidney Int, 2003, 63(3):1003–1011.

[22] Rodriguez Garcia M, Naves Diaz M, Cannata Andia JB, *Bone metabolism, vascular calcifications and mortality: associations beyond mere coincidence*, J Nephrol, 2005, 18(4):458–463.

[23] Goldsmith D, Ritz E, Covic A, *Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease?* Kidney Int, 2004, 66(4):1315–1333.

[24] Ketteler M, Gross ML, Ritz E, *Calcification and cardiovascular problems in renal failure*, Kidney Int Suppl, 2005, 94:S120–S127.

[25] London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H, *Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality*, Nephrol Dial Transplant, 2003, 18(9):1731–1740.

[26] Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM, *Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?* J Am Coll Cardiol, 2002, 39(4):695–701.

[27] Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H, *Vascular calcification and inorganic phosphate*, Am J Kidney Dis, 2001, 38(4 Suppl 1):S34–S37.

[28] Qunibi WY, Nolan CA, Ayus JC, *Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon*, Kidney Int Suppl, 2002, 82:S73–S80.

[29] London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC, *Arterial calcifications and bone histomorphometry in end-stage renal disease*, J Am Soc Nephrol, 2004, 15(7):1943–1951.

[30] Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V, *Aortic calcification and the risk of osteoporosis and fractures*, J Clin Endocrinol Metab, 2004, 89(9):4246–4253.

[31] McCullough PA, Agrawal V, Danielewicz E, Abela GS, *Accelerated atherosclerotic calcification and Monckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease*, Clin J Am Soc Nephrol, 2008, 3(6):1585–1598.

[32] Amann K, *Media calcification and intima calcification are distinct entities in chronic kidney disease*, Clin J Am Soc Nephrol, 2008, 3(6):1599–1605.

[33] Neven E, De Schutter TM, Behets GJ, Gupta A, D'Haese PC, *Iron and vascular calcification. Is there a link?* Nephrol Dial Transplant, 2011, 26(4):1137–1145.

[34] Okuno S, Ishimura E, Kitatani K, Fujino Y, Kohno K, Maeno Y, Maekawa K, Yamakawa T, Imanishi Y, Inaba M, Nishizawa Y, *Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients*, Am J Kidney Dis, 2007, 49(3):417–425.

[35] Shao JS, Cheng SL, Sadhu J, Towler DA, *Inflammation and the osteogenic regulation of vascular calcification: a review and perspective*, Hypertension, 2010, 55(3):579–592.

[36] Demer LL, Tintut Y, *Vascular calcification: pathobiology of a multifaceted disease*, Circulation, 2008, 117(22):2938–2948.

[37] Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM, McDonald JM, Chen Y, *Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling*, J Biol Chem, 2008, 283(22):15319–15327.

[38] Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL, *Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies*, Circ Res, 2000, 87(11):1055–1062.

[39] Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM, *Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis*, Circulation, 2008, 118(17):1748–1757.

[40] Liberman M, Bassi E, Martinatti MK, Lario FC, Wosniak J Jr, Pomerantzeff PM, Laurindo FR, *Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification*, Arterioscler Thromb Vasc Biol, 2008, 28(3):463–470.

[41] You H, Yang H, Zhu Q, Li M, Xue J, Gu Y, Lin S, Ding F, *Advanced oxidation protein products induce vascular calcification by promoting osteoblastic trans-differentiation of smooth muscle cells via oxidative stress and ERK pathway*, Ren Fail, 2009, 31(4):313–319.

[42] Guerin A, *Coronary calcifications: lessons from histology in CKD patients*, Am J Kidney Dis, 2010, 55(1):1–4.

[43] Fitzpatrick LA, Severson A, Edwards WD, Ingram RT, *Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis*, J Clin Invest, 1994, 94(4):1597–1604.

[44] Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM, *Exploring the biology of vascular calcification in chronic kidney disease: what's circulating?* Kidney Int, 2008, 73(4):384–390.

[45] Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, Kohler RH, Jaffer FA, Aikawa M, Weissleder R, *Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo*, Circulation, 2007, 116(24):2841–2850.

[46] Hsu JJ, Tintut Y, Demer LL, *Vitamin D and osteogenic differentiation in the artery wall*, Clin J Am Soc Nephrol, 2008, 3(5):1542–1547.

[47] Moe SM, Chen XN, *Pathophysiology of vascular calcification in chronic kidney disease*, Circ Res, 2004, 95(6):560–567.

[48] Majesky MW, *Developmental basis of vascular smooth muscle diversity*, Arterioscler Thromb Vasc Biol, 2007, 27(6):1248–1258.

[49] Nakano T, Ninomiya T, Sumiyoshi S, Fujii H, Doi Y, Hirakata H, Tsuruya K, Iida M, Kiyohara Y, Sueishi K, *Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama Study*, Am J Kidney Dis, 2010, 55(1):21–30.

[50] Brandenburg VM, Ketteler M, Rodriguez M, *Ten years of progress in our understanding of uremic vascular calcification and disease: a decade summarized in 20 steps*, Kidney Int Suppl, 2011, 1(4):116–121.

[51] Bover J, Cozzolino M, *Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation*, Kidney Int Suppl, 2011, 1:122–129.

[52] Llach F, Bover J, Renal osteodystrophies. In: Brenner BM (ed), *The kidney*, W.B. Saunders Co., Philadelphia, 2000, 2103–2186.

[53] Bover J, Rodriguez M, Trinidad P, Jara A, Martinez ME, Machado L, Llach F, Felsenfeld AJ, *Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat*, Kidney Int, 1994, 45(4):953–961.

[54] Cozzolino M, Pasho S, Fallabrino G, Olivi L, Gallieni M, Brancaccio D, *Pathogenesis of secondary hyperparathyroidism*, Int J Artif Organs, 2009, 32(2):75–80.

[55] Andress DL, *Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation*, Kidney Int, 2006, 69(1):33–43.

[56] Rojas-Rivera J, De La Piedra C, Ramos A, Ortiz A, Egido J, *The expanding spectrum of biological actions of vitamin D*, Nephrol Dial Transplant, 2010, 25(9):2850–2865.

[57] Cozzolino M, Ciceri P, Volpi EM, Olivi L, Messa PG, *Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease*, Blood Purif, 2009, 27(4):338–344.

[58] Krajisnik T, Olauson H, Mirza MA, Hellman P, Akerström G, Westin G, Larsson TE, Björklund P, *Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients*, Kidney Int, 2010, 78(10):1024–1032.

[59] Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G; Kidney Disease: Improving Global Outcomes (KDIGO), *Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)*, Kidney Int, 2006, 69(11):1945–1953.

[60] Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, *KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)*, Kidney Int Suppl, 2009, 113:S1–S130.

[61] Bover J, Cozzolino M, *Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation*, Kidney Int Suppl, 2011, 1(4):122–129.

[62] Moe SM, Drüeke T, Lameire N, Eknoyan G, *Chronic kidney disease-mineral-bone disorder: a new paradigm*, Adv Chronic Kidney Dis, 2007, 14(1):3–12.

[63] Frazão JM, Martins P, *Adynamic bone disease: clinical and therapeutic implications*, Curr Opin Nephrol Hypertens, 2009, 18(4):303–307.

[64] Cozzolino M, Ketteler M, *The link between bone and cardiovascular disease in CKD: new insights into pathogenesis and treatment*, Int J Artif Organs, 2009, 32(2):65–66.

[65] Guérin AP, London GM, Marchais SJ, Metivier F, *Arterial stiffening and vascular calcifications in end-stage renal disease*, Nephrol Dial Transplant, 2000, 15(7):1014–1021.

[66] Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group, *Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients*, Kidney Int, 2002, 62(1):245–252.

[67] Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH, *Evidence for abnormal calcium homeostasis in patients with adynamic bone disease*, Kidney Int, 1994, 46(3):855–861.

[68] Takei T, Otsubo S, Uchida K, Matsugami K, Mimuro T, Kabaya T, Akiba T, Nitta K, *Effects of Sevelamer on the progression of vascular calcification in patients on chronic haemodialysis*, Nephron Clin Pract, 2008, 108(4):c278–c283.

[69] Genzyme, *Renvela (sevelamer carbonate) tablets prescribing information*, Cambridge, MA, 2007.

[70] Genzyme, *Renvela (sevelamer hydrochloride) tablets prescribing information*, Cambridge, MA, 2007.

[71] Hercz G, Kraut JA, Andress DA, Howard N, Roberts C, Shinaberger JH, Sherrard DJ, Coburn JW, *Use of calcium carbonate as a phosphate binder in dialysis patients*, Miner Electrolyte Metab, 1986, 12(5–6):314–319.

[72] Murshed M, Harmey D, Millán JL, McKee MD, Karsenty G, *Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone*, Genes Dev, 2005, 19(9):1093–1104.

[73] Riser BL, Barreto FC, Rezg R, Valaitis PW, Cook CS, White JA, Gass JH, Maizel J, Louvet L, Drueke TB, Holmes CJ, Massy ZA, *Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia*, Nephrol Dial Transplant, 2011, 26(10):3349–3357.

[74] Sigrist MK, Taal MW, Bungay P, McIntyre CW, *Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease*, Clin J Am Soc Nephrol, 2007, 2(6):1241–1248.

Corresponding author

Ionel Alexandru Checheriță, Assistant Lecturer, MD, PhD, 13 Vitan–Bârzeşti Highroad, 4th Sector, 042122 Bucharest, Romania; Phone +4021–334 50 75, Fax +4021–334 59 70, e-mail: fizij@yahoo.com